Skip to main content

Biosimilars

Biosimilars

Biosimilar Uptake of Filgrastim and Impact on Spending in Medicare Part D from 2015 to 2019

Biosimilars

Evaluation of Real-World Cost-Savings and Utilization of Biosimilar Drugs in a Community-Based Oncology Practice

Biosimilars

Utilization and Clinical Characteristics for the Trastuzumab Originator, Biosimilars, and Other HER2 Inhibitors

Biosimilars

Cost-Savings from Conversion to Biosimilar Pegfilgrastim-cbqv Allowed Budget-Neutral Expanded Access to Antineoplastic Therapy

Biosimilars

Biosimilars

Bioequivalence of Bevacizumab Reference and Its Biosimilar BCD-021 in Nonsquamous NSCLC

Biosimilars

Five-Year Follow-Up of a Comparative Phase 3 Study of SB3 and Trastuzumab Reference in HER2-Positive Early or Locally Advanced Breast Cancer

Biosimilars

Comparative Analysis of Safety, Efficacy, and Immunogenicity of Trastuzumab Reference and Its Biosimilar TX05 in HER2-Positive Early Breast Cancer

Biosimilars

Oncologists’ Knowledge and Perspectives on the Use of Biosimilars

Biosimilars

A Successful Model of Biosimilar Adoption in a Community Oncology Practice

1
2
3
4
5
6

Page 3 of 8
Results 21 - 30 of 73